List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Trigeminal Neuralgia (Tic Douloureux) - Overview
Trigeminal Neuralgia (Tic Douloureux) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Trigeminal Neuralgia (Tic Douloureux) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Trigeminal Neuralgia (Tic Douloureux) - Companies Involved in Therapeutics Development
Amgen Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Grace Therapeutics LLC
InMed Pharmaceuticals Inc
Merz Pharma GmbH & Co KgaA
Noveome Biotherapeutics Inc
OliPass Corporation
PixarBio Corp
Trigeminal Neuralgia (Tic Douloureux) - Drug Profiles
carbamazepine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DKI-561 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INM-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLP-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vixotrigine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects
Trigeminal Neuralgia (Tic Douloureux) - Product Development Milestones
Featured News & Press Releases
Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial
Feb 27, 2018: PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat Trigeminal Neuralgia and Post-Surgical Pain
Sep 15, 2016: PixarBio CEO Frank Reynolds to Present NeuroRelease a Non-Addictive Morphine Replacement at the 2016 Aegis Capital Growth Conference in Las Vegas, NV on September 21, 2016
Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch
Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs
Mar 03, 2016: PixarBio’s Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016
Nov 30, 2015: PixarBio’s Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY
Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia
Sep 23, 2014: Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Amgen Inc, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biogen Inc, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Grace Therapeutics LLC, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by InMed Pharmaceuticals Inc, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noveome Biotherapeutics Inc, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by OliPass Corporation, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by PixarBio Corp, H1 2020
Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects, H1 2020

List of Figures
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• Amgen Inc
• Biogen Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Grace Therapeutics LLC
• InMed Pharmaceuticals Inc
• Merz Pharma GmbH & Co KgaA
• Noveome Biotherapeutics Inc
• OliPass Corporation
• PixarBio Corp